Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;32(6):1404-1413.
doi: 10.1038/s41375-018-0133-x. Epub 2018 Apr 26.

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial

Charles Dumontet  1 , Cyrille Hulin  2 , Meletios A Dimopoulos  3 , Andrew Belch  4 , Angela Dispenzieri  5 , Heinz Ludwig  6 , Philippe Rodon  7 , Jan Van Droogenbroeck  8 , Lugui Qiu  9 , Michele Cavo  10 , Ann Van de Velde  11 , Juan José Lahuerta  12 , Olivier Allangba  13 , Jae Hoon Lee  14 , Eileen Boyle  15 , Aurore Perrot  16 , Philippe Moreau  17 , Salomon Manier  15 , Michel Attal  18 , Murielle Roussel  19 , Mohamad Mohty  20 , Jean Yves Mary  21 , Alexandre Civet  22 , Bruno Costa  23 , Antoine Tinel  23 , Yann Gaston-Mathé  24 , Thierry Facon  25
Affiliations

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial

Charles Dumontet et al. Leukemia. 2018 Jun.

Abstract

Infections are a major cause of death in patients with multiple myeloma. A post hoc analysis of the phase 3 FIRST trial was conducted to characterize treatment-emergent (TE) infections and study risk factors for TE grade ≥ 3 infection. The number of TE infections/month was highest during the first 4 months of treatment (defined as early infection). Of 1613 treated patients, 340 (21.1%) experienced TE grade ≥ 3 infections in the first 18 months and 56.2% of these patients experienced their first grade ≥ 3 infection in the first 4 months. Risk of early infection was similar regardless of treatment. Based on the analyses of data in 1378 patients through multivariate logistic regression, a predictive model of first TE grade ≥ 3 infection in the first 4 months retained Eastern Cooperative Oncology Group performance status and serum β2-microglobulin, lactate dehydrogenase, and hemoglobin levels to define high- and low-risk groups showing significantly different rates of infection (24.0% vs. 7.0%, respectively; P < 0.0001). The predictive model was validated with data from three clinical trials. This predictive model of early TE grade ≥ 3 infection may be applied in the clinical setting to guide infection monitoring and strategies for infection prevention.

PubMed Disclaimer

Conflict of interest statement

Charles Dumontet has received honoraria from Sanofi and Janssen, has received fees for a consulting/advisory role from Merck, and has received research funding from Roche. Cyrille Hulin has received honoraria from Celgene, Amgen, Bristol-Myers Squibb, Novartis, Janssen-Cilag, and Takeda. Meletios A. Dimopoulos has received honoraria from Amgen, Celgene, Janssen, and Takeda and has received fees for a consulting/advisory role from Amgen, Celgene, Janssen, and Takeda. Angela Dispenzieri has received research funding from Alnylam, Celgene, Pfizer, Prothena, and Takeda. Heinz Ludwig has received speakers’ bureau fees from Celgene, Janssen, Takeda, and Amgen and has received research funding from Takeda and Amgen. Michele Cavo has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda. Juan José Lahuerta has received fees for a consulting/advisory role from Celgene, Janssen, and Takeda. Olivier Allangba has received fees for a consulting/advisory role from Novartis and has received travel, accommodations, and expenses from Takeda, Pfizer, Celgene, Amgen, and Roche. Eileen Boyle has received fees for a consulting/advisory role from Celgene. Aurore Perrot has received honoraria and fees for a consulting/advisory role from Celgene, Janssen, Takeda, and Bristol-Myers Squibb. Philippe Moreau has received honoraria from Celgene, Takeda, Novartis, Amgen, and Janssen-Cilag and has received fees for a consulting/advisory role from Celgene, Takeda, Novartis, Amgen, and Janssen. Murielle Roussel has received research funding from Amgen, Celgene, and Janssen. Mohamad Mohty has received honoraria from Celgene, Janssen, Bristol-Myers Squibb, Takeda, Novartis, and Amgen; fees for consulting/advisory role from Celgene, Janssen, Bristol-Myers Squibb, Takeda, Novartis, and Amgen; speakers’ bureau fees from Janssen and Sanofi; research funding from Sanofi; and travel, accommodations, expenses from Sanofi, JAZZ, Novartis, Janssen, and Amgen. Alexandre Civet has received fees for a consulting/advisory role from Celgene. Bruno Costa is an employee of and owns stock in Celgene. Antoine Tinel is an employee of and owns stock in Celgene. Yann Gaston-Mathé is an employee of IntegraGen, has received fees for a consulting/advisory role from Celgene, and has received travel, accommodations, expenses from Celgene. Thierry Facon has received fees for a consulting/advisory role from Amgen, Celgene, Janssen, Karyopharm, PharmaMar, and Takeda and has received speakers’ bureau fees from Amgen, Celgene, Janssen, and Takeda. Andrew Belch, Philippe Rodon, Jan Van Droogenbroeck, Lugui Qiu, Ann Van de Velde, Jae Hoon Lee, Salomon Manier, Michel Attal, and Jean Yves Mary declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Treatment-emergent (TE) infections in the FIRST trial. a Number of TE infections by month in the first 18 months of the FIRST trial (1613 treated patients). The numbers above the bars indicate the total number of TE infections of all grades during the treatment month. b Number of new patients with TE grade ≥ 3 infections by month in the first 18 months of the FIRST trial (1613 treated patients)
Fig. 2
Fig. 2
Time to first grade ≥ 3 TE infection in the first 4 months for high- and low-risk groups in the a MM-020 (n = 1602), b MM-015 (n = 452), c MM-009/10 (n = 643), d MM-003 (n = 425) populations. C-index concordance index, HR hazard ratio
See this image and copyright information in PMC

References

    1. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49:1211–25. doi: 10.1086/605664. - DOI - PubMed
    1. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23:9219–26. doi: 10.1200/JCO.2005.03.2086. - DOI - PubMed
    1. Hsu P, Lin TW, Gau JP, Yu YB, Hsiao LT, Tzeng CH, et al. Risk of Early mortality in patients with newly diagnosed multiple myeloma. Med (Baltim) 2015;94:e2305. doi: 10.1097/MD.0000000000002305. - DOI - PMC - PubMed
    1. Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107–13. doi: 10.3324/haematol.2014.107714. - DOI - PMC - PubMed
    1. Ying L, YinHui T, Yunliang Z, Sun H. Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis. Oncotarget. 2017;8:46593–600. - PMC - PubMed

Publication types